154 results about "Alpha-Tocopherol" patented technology

These and other objects of this invention are achieved by providing a novel method and compositions for the clinical treatment of chronic inflammatory diseases. This invention involves use of systemically administered compositions which include primary amine derivatives of benzoic acid as carbonyl trapping agents. These primary therapeutic agents act by chemically binding to and sequestering the aldehyde and/or ketone products of lipid peroxidation. Increased levels of lipid peroxidation have been repeatedly demonstrated as a part of the non-enzymatic "inflammatory cascade" process which underlies the secondary etiology of chronic inflammatory diseases. p-Aminobenzoic acid (or PABA) is an example of the primary therapeutic agent of the present invention. PABA has a small molecular weight, is water soluble, has a primary amine group that reacts with carbonyl-containing metabolites under physiological conditions and is tolerated by the body in relatively high dosages and for extended periods. The carbonyl sequestering agents are used in combination with at least one co-agent so as to produce an additional beneficial physiological effect of an anti-inflammatory nature. Such compositions are administered systemically entirely via the oral route. Co-agents of the present invention include anti-oxidants and free radical trapping compounds (e.g., alpha-tocopherol), compounds having indirect anti-oxidant activity (e.g., selenium), vitamins (e.g., pyridoxine HCl), compounds which facilitate kidney drug elimination (e.g., glycine), metabolites at risk of depletion (e.g., pantothenic acid), sulfhydryl containing chemicals (e.g., methionine), compounds which facilitate glutathione activity (e.g., N-acetylcysteine), and non-absorbable polyamine co-agents (e.g., chitosan).

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

A dietary supplement of mitochondrial nutrients is designed for relieving stress, preventing and improving stress-related disorders, such as chronic fatigue syndrome, diabetes, age-associated cognitive dysfunction and diseases (Parkinson's and Alzheimer's disease). The supplement composition has the following nutrients: B vitamins (cyanocobalamin 2-1,000 ug, thiamin 1-1,000 mg, niacin 15-2,000 mg, pyridoxine 1-1,000 mg, Pantothenate 5-150 mg, folic acid 400-40,000 ug), alpha-tocopherol 10-800 mg, ascorbic acid 50-10,000 mg, calcium 20-2,000 mg, vitamin A 200-10,000 ug, alpha-lipoic acid 100-1,000 mg, N-acetyl cysteine 100-3,000 mg, L-carnosine 100-9,000 mg, tyrosine 100-9,000 mg, vanillin 10-100 mg, phosphatidylserine 10-800 mg, resveratrol 10-50 mg, dehydroepiandrosterone 1-50 mg, and melatonin 0.1-3 mg, all of which have been individually used experimentally or clinically for relieving stress, preventing and treating age- and stress-related disorders and diseases but no combination of these compounds has been used. Many embodiments also contain at least one adjunct ingredient such as coenzyme Q 10-200 mg, acetyl-L-carnitine 100-2,000 mg, choline 50-1,000 mg, and creatine 100-2,000 mg.

The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent.

Disclosed are skin care compositions comprising a plant-derived protein extract, such as a soy protein extract or a colloidal oatmeal preparation, supplemented by an enrichment composition, such as a non-alpha tocopherol, and methods of making and using such compositions.

The invention provides a less-harmful nontoxic rubber vehicle sealing strip which has excellent processability and physical properties and belongs to an environment friendly sulfidizing system. Main raw materials are as follows: 200 plus or minus 10 portions of ethylene propylene diene methylene, and 150 plus or minus 10portions of carbon black; 20 plus or minus 2 portions of light super fine calcium carbonate and 30 plus or minus 3 portions of talc as fillers; 20 plus or minus 2 portions of high-flash paraffin oil or styrene/Alpha-methyl styrene/vinyl toluene terpolymer as a softener; 10 plus or minus 1 portions of aluminum hydroxide as a flame retardant; 5 plus or minus 0.5 portions of zinc oxide and 2 plus or minus 0.2 portions of stearic acid as active agents together; 4 plus or minus 0.4 portions of polyethylene glycol of a hydroxyl polar group as an additive; 5 plus or minus 0.5 portions of calcium oxide as a neutralizer; 4 plus or minus 0.4 portions of nitrogen-free sulfidation material which is mainly sulphur; and 0.3 plus or minus 0.03 portion of Alpha-tocopherol as an inhibitor. The less harmful nontoxic rubber vehicle sealing strip can not only reduce environmental pollution, but also maintain reasonable cost.

The invention discloses a content analysis and detection method of twelve compound vitamins for injection. Liposoluble components including vitamin A palmitate, vitamin D3 and racemic alpha-tocopherol are detected under the same high-performance liquid phase method conditions, a test solution is prepared by extracting a preparation content by non-polar organic solvent, and the detection wavelength is 265+/-3nm. Water-soluble components including cocarboxylase tetrahydrate, riboflavin sodium phosphate, vitamin B6, vitamin C, nicotinamide, folic acid and dexpanthenol are detected under the same high-performance liquid phase method conditions, and the detection wavelength is 210+/-3nm. Biotin and vitamin B12 are subjected to high-performance liquid phase method based detection, the detection wavelength is 200-600nm, and the preferable detection wavelength for the vitamin B12 is 550+/-3nm. The method has high applicability.

Compositions and methods of use of annatto extracts [350-450 Dalton molecular weight fraction] including tocotrienols and tocopherols with an appropriate spectrum. This spectrum includes but not limited to low alpha tocopherol, high delta- and gamma-tocols, and mixtures with other extracts [350-450 Dalton molecular weight fraction] like palm and rice and/or nutrients.

The present invention relates to pharmaceutical compositions in form of solid lipidic nanospheres able to rapidly penetrate into the cells, comprising as an active substance a lipidic substance consisting of an ester of alpha-tocopherol or delta-tocopherol or of cholesterol or of glycerol with a carboxylic acid selected from acetic acid, propionic acid, butyric acid and succinic acid, useful in the treatment of tumoral pathologies and of Mediterranean anaemia.

The present invention belongs to technical field of medicine, and relates to the preparing of cleavable polyethylene glycol (PEG) lipid derivative and an application thereof in the liquid particle preparation. The general formula is as follows: CH3O(CH2CH2O)n-R-O-R, n=5-5000. The molecular weight of PEG is 300-30000. R represents one group selected from hemisuccinate group and carbomethoxy. The liposoluble fragment represented by R comprises one component selected from cholesterol, sitosterol, alpha-tocopherol. According to the invention, polyethylene glycol are connected with lipoid derivatives such as cholesterol, alpha-tocopherol, etc. through ester linkage. The cleavable PEG lipid derivative can be applied to the modification of liquid particle preparation. On one hand, the PEG lipid derivative has appropriate adhesive force of the surface of liquid particle preparation and guarantees enough holding time of PEG lipid derivative in blood. On the other hand, the PEG lipid derivative can gradually break away from the surface of preparation in the circulation process. The particle preparation which only comprises a few polyethylene glycol on the surface can combine and phagocytose the pathological cell. The medicine is delivered into the cell and therefore has the function of selectively killing the pathological cell.

The invention relates to solid dispersion as well as a preparation method and an application thereof. The solid dispersion is prepared from indissolvable drugs, a surfactant and a water-soluble polymer material with a spray drying method after mixing and heating dissolution, wherein the surfactant is selected from at least one of sodium dodecyl sulfate, poloxamer, tween, alpha-tocopherol, succinate, polyethylene glycol, sodium cholate and polyethylene glycol/vinyl caprolactam/vinyl acetate copolymer; the water-soluble polymer material is selected from at least one of povidone, copovidone, hydroxypropyl methylcellulose and polyethylene glycol. An organic solvent is not required when the solid dispersion is prepared with the spray drying method, and the problem of organic solvent residues is solved. By means of the solid dispersion, the dissolvability of the indissolvable drugs is increased, the dissolution speed and the dissolubility are remarkably increased, and the bioavailability of the indissolvable drugs is improved.

Disclosed herein is an aqueous emulsion of alpha-tocopherol and preferably other forms of vitamin E, coenzyme Q10, beta-carotene, vitamin D, and vitamin K useful for treating complications of cystic fibrosis. The aqueous emulsion improves malabsorption and immunity against infection, and reduces oxidative stress and respiratory complications in cystic fibrosis.

Disclosed are nutritional formulas generally, and infant formulas specifically, including a combination of RRR-alpha tocopherol, LC-PUFAs, and optionally vitamin C. The combination enhances brain development and improves cognitive performance in an individual, and specifically in an infant.

A method for synthesizing natural alpha-tocopherol succinic acid monoester using lipase pertains to the field of biological chemicals, which is characterized in that the preparation method includes: adding the substrate of natural alpha-tocopherol and succinic anhydride at molar ratio of 1:1-1:8 in an organic solvent, adding lipase to start the reaction, oscillating or mixing reaction 20-72 hours under the conditions of 20-45 DEG C, wherein, the conversion rate of the alpha-tocopherol is 80-98.39%. Compared with the prior industry process in which esterification is performed at high-temperature by using high toxicity chemical catalyst under, the method has advantages of mild reaction conditions (room temperature, atmospheric pressure), low energy consumption, non-toxic catalyst, specificity, high reaction efficiency fewer accessory substances, and the like.

The invention provides a pharmaceutical composition of 12 complex vitamins for injection and a preparation method thereof. The pharmaceutical composition of 12 complex vitamins for injection provided by the invention comprises the active ingredients of vitamin A palmitate, cholecalciferol, racemic alpha-tocopherol, ascorbic acid, nicotinamide, dexpanthenol, pyridoxine hydrochloride, riboflavin sodium phosphate, tetrahydrate thiamine pyrophosphate, folic acid, D-biotin and cyanocobalamin, and auxiliary materials namely polysorbate 80 and mannitol. The prescription provided by the invention does not contain auxiliary material glycocholic acid, and can be clinically used for people with over-high glycocholic acid.

The invention discloses a low serum amniotic fluid cell culture medium. On the basis of mixing a basal culture medium RPMI 1640 and a basal culture medium alpha MEN according to the proportion of one to one, the components of insulin, a basic fibroblast growth factor (bFGF), an epidermal growth factor (EGF), bovine serum albumin (BSA), hydrocortisone, alpha tocopherol, NaHCO3, ferric citrate, tween 80, ethanol amine, oleic acid, linoleic acid and fetal calf serum are added, wherein addition of fetal calf serum content accounts for not more than 1% of the total volume of the low serum amniotic fluid cell culture medium. According to the low serum amniotic fluid cell culture medium, compared with an existing public technology, the serum content and the cost are reduced, the effect is significantly improved, colony forming efficiency and colony growth speed are increased obviously, in a short time, a great number of aminotic cells in a division phase can be obtained through culture, and the requirements of clinical diagnoses and scientific research can be met.

The invention discloses a method for preparing low-benzopyrene high-purity d-alpha tocopherol acetate. The method comprises the following steps of: mixing d-alpha tocopherol, an inert organic solvent and a catalyst in a certain ratio, controlling the temperature, performing esterification reaction on the mixture and acetic anhydride, mixing obtained crude d-alpha tocopherol acetate and a polar solvent, loading to a column, adsorbing by using resin so as to remove impurities, mixing the obtained product and the inert organic solvent, adding a removal agent in a certain ratio, circulating at the constant temperature of 60 DEG C for 2 hours in an external circulation mode, filtering, concentrating, desolventizing, and performing short-path molecular distillation refinement under high vacuum conditions to obtain the low-benzopyrene high-purity d-alpha tocopherol acetate. The content of the obtained product is high, and the content of the d-alpha tocopherol acetate is more than or equal to 98 percent; the specific rotation is more than or equal to +24 degrees; the concentration of heavy metals (based on Pb) is less than or equal to 10ppm; and the concentration of benzopyrene is less than or equal to 2ppb. The quality of products meets the standards established by developed countries in Europe and America.

A micronutrient formulation system is provided and the system comprises: a first composition comprising alpha tocopherol and derivative esters of alpha tocopherol, the derivative esters of alpha tocopherol being selected from a group consisting essentially of alpha tocopheryl acetate, alpha tocopheryl palmitate, alpha tocopheryl succinate, alpha tocopheryl nicotinate and mixtures thereof; a second composition comprising vitamin A and natural-mixed carotenoids; a third composition comprising calcium ascorbate; a fourth composition selected from a group consisting essentially of B-vitamins, selenium, zinc, magnesium, chromium and mixtures thereof; and a fifth composition selected from a group consisting essentially of alpha lipoic acid, co-enzyme Q10, L-carnitine, n-acetyl cysteine and mixtures thereof, wherein said formulation is without iron, copper and manganese.